U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H22N2O
Molecular Weight 246.348
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Sophocarpine

SMILES

[H][C@]12CCCN3CCC[C@]([H])([C@@]4([H])CC=CC(=O)N4C1)[C@]23[H]

InChI

InChIKey=AAGFPTSOPGCENQ-JLNYLFASSA-N
InChI=1S/C15H22N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h1,7,11-13,15H,2-6,8-10H2/t11-,12+,13+,15-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H22N2O
Molecular Weight 246.348
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: doi: 10.1248/cpb.13.482
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/24587659 | https://www.ncbi.nlm.nih.gov/pubmed/23395669 | https://www.ncbi.nlm.nih.gov/pubmed/18379053

Sophocarpine is a dehydrogenation derivative of the bis-quinolizidine alkaloid matrine. Sophocarpine is also an active component in sophora alkaloids, which possess a variety of pharmacological effects such as anti-inflammation, immunity regulation, antivirus, and anti-tumor actions. Sophocarpine is able to block HERG K+ channel. It is Na+ channel inward current inhibitor. It activates the AMPK signaling pathway and inhibits the TLR4-downstream pathway.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced EMT with sophocarpine.
2016-06-28
RETRACTED: Sophocarpine displays anti-inflammatory effect via inhibiting TLR4 and TLR4 downstream pathways on LPS-induced mastitis in the mammary gland of mice.
2016-06
Inhibition of Sophocarpine on Poly I: C/D-GalN-Induced Immunological Liver Injury in Mice.
2016
[Mechanism of sophocarpine in treating experimental colitis in mice].
2015-08
Patents

Sample Use Guides

Rat: 20 mg/kg once a day
Route of Administration: Intraperitoneal
In the presence of ATX II, SOP (20, 40, and 80 mM) reversed the increased INa.L in a concentration-dependent manner.
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:38:03 GMT 2025
Edited
by admin
on Mon Mar 31 22:38:03 GMT 2025
Record UNII
X9X8U6P2NP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
(-)-Sophocarpine
Preferred Name English
Sophocarpine
Common Name English
(7aS,13aR,13bR,13cS)-2,3,6,7,7a,8,13,13a,13b,13c-Decahydro-1H,5H,10H-dipyrido[2,1-f:3?,2?,1?-ij][1,6]naphthyridin-10-one
Systematic Name English
1H,5H,10H-Dipyrido[2,1-f:3?,2?,1?-ij][1,6]naphthyridin-10-one, 2,3,6,7,7a,8,13,13a,13b,13c-decahydro-, (7aS,13aR,13bR,13cS)-
Systematic Name English
13,14-Dehydromatrine
Common Name English
Matridin-15-one, 13,14-didehydro-
Common Name English
13,14-Didehydromatrine
Common Name English
Code System Code Type Description
FDA UNII
X9X8U6P2NP
Created by admin on Mon Mar 31 22:38:03 GMT 2025 , Edited by admin on Mon Mar 31 22:38:03 GMT 2025
PRIMARY
EPA CompTox
DTXSID90215126
Created by admin on Mon Mar 31 22:38:03 GMT 2025 , Edited by admin on Mon Mar 31 22:38:03 GMT 2025
PRIMARY
PUBCHEM
115269
Created by admin on Mon Mar 31 22:38:03 GMT 2025 , Edited by admin on Mon Mar 31 22:38:03 GMT 2025
PRIMARY
CAS
6483-15-4
Created by admin on Mon Mar 31 22:38:03 GMT 2025 , Edited by admin on Mon Mar 31 22:38:03 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT